Related Experiment Video
Updated: Jul 15, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Meglitinide analogues for type 2 diabetes mellitus
C Black1, P Donnelly, L McIntyre
1University of Aberdeen, Public Health, Polwarth Building, Foresterhill, Aberdeen, Scotland, UK AB25 2ZD. corri.black@abdn.ac.uk
The Cochrane Database of Systematic Reviews
|April 20, 2007
Summary
Meglitinide analogues effectively lower glycosylated hemoglobin in type 2 diabetes, comparable to metformin. However, long-term outcomes like mortality remain unstudied.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus involves impaired insulin secretion.
- Meglitinide analogues are oral hypoglycemic agents that enhance early-phase insulin release.
Purpose of the Study:
- To review the effects of meglitinide analogues in type 2 diabetes patients.
Main Methods:
- Searched multiple databases (Cochrane, MEDLINE, EMBASE) and contacted manufacturers.
- Included randomized controlled trials of at least 10 weeks comparing meglitinides to placebo, metformin, or insulin combinations.
- Data extraction and quality assessment were performed independently by two authors.
Main Results:
- Fifteen trials with 3781 participants were analyzed; no mortality or morbidity data were reported.
- Meglinitides (repaglinide, nateglinide) reduced HbA1c compared to placebo.
- Repaglinide showed similar HbA1c reduction to metformin, while nateglinide showed similar or slightly less effect. Weight gain was greater with meglitinides than metformin, and hypoglycemia occurred more frequently.
Conclusions:
- Meglinitides offer an alternative to metformin for type 2 diabetes, especially when metformin is contraindicated or poorly tolerated.
- Further research is needed to determine the long-term effects of meglitinides on critical outcomes, including mortality.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...